Health & Medicine3 weeks ago

Trial reports how a blood test performed in screening for several cancers

The analysis found low rates of positive results, with varying ability to detect cancers across three annual screening rounds.

High evidenceHuman studySome caution advised

Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.

The test was added to usual care for people in the intervention group, while the control group received usual care alone. Participants with positive results were referred through National Health Service diagnostic pathways, with referrals informed by the test’s predicted cancer location.

Across three annual rounds, the test’s positive predictive value ranged from 45.8% to 58.0%, meaning that roughly half of positive results were associated with a primary cancer detected in the study. Sensitivity was lower and varied by cancer type; the reported analyses were descriptive and did not test whether the screening strategy improved health outcomes.

The question examined

The researchers examined prespecified secondary measures of a multi-cancer early detection test in the NHS-Galleri randomized controlled trial. The trial included 142,250 adults aged 50–77 who were randomized 1:1 to an intervention group receiving the test in addition to usual care or a control group receiving usual care. This report focused on evaluable intervention-group participants across three annual screening rounds. Participants with positive test results were referred for diagnostic workup through standard NHS pathways. The measures included the proportion of positive tests, cancer detection rate, positive and negative predictive values, specificity, sensitivity, and accuracy in identifying the likely cancer signal origin.

What the study found

Positive test results were returned for 722 of 70,325 participants in round 1 (1.03%), 518 of 64,498 in round 2 (0.80%), and 561 of 62,323 in round 3 (0.90%). Across the rounds, 937 participants had primary cancers detected by the test. Cancer detection rates were 0.60%, 0.40%, and 0.41%, respectively. Positive predictive value was 58.0%, 50.4%, and 45.8%, while negative predictive value was 98.98%, 98.90%, and 98.86%. Specificity ranged from 99.50% to 99.60%. Episode sensitivity ranged from 26.7% to 37.2% for all cancers and from 47.6% to 63.4% for 12 prespecified cancer types. The test identified the likely cancer signal origin with 91.1% to 93.6% accuracy. These were descriptive findings, and the abstract states that the trial’s primary endpoint—a reduction in stage III or IV cancer diagnoses—was not met.

Where this may apply

These findings are most directly relevant to adults aged 50–77 undergoing screening in a setting similar to the NHS trial, where the test was added to usual care and positive results were evaluated through NHS diagnostic pathways. They may not apply in the same way to younger or older people, different health systems, or populations with different cancer risks. The findings do not establish a health benefit for any individual or show that the test reduces advanced cancer or deaths.

The significance

The results describe how this test performed when added to usual care in a large NHS-based screening trial, including how often it produced positive results and how often those results were linked with a detected primary cancer. They do not show that using the test reduces advanced cancer diagnoses, illness, or deaths. The reported performance measures therefore provide information about the test itself, not proof of a health benefit from screening.

Limitations & evidence assessment

The reported results were prespecified secondary endpoints and were descriptive; there was no hypothesis testing for these analyses. The trial’s primary endpoint, a reduction in stage III or IV cancer diagnoses, was not met. The abstract does not provide enough information to assess all details of follow-up, the completeness of cancer ascertainment, or how the performance measures varied across participant subgroups. Performance measures from the intervention group alone do not establish that the screening strategy improves patient outcomes, and a negative result does not mean that cancer was ruled out in every individual.

Why this evidence level: Large randomized trial (detected n≈142250 ≥ 500).

Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.